Accelerate to discover

Homepage>Discover>A carboxymethyl dextran-based polymeric conjugate as the antigen carrier for cancer immunotherapy

Back to filter

Aug 16, 2024

We invite you to learn more about MERSCOPE Ultra Platform. Webinar featuring Rob Mathis (Global Instrument Product...

Single-Cell Genomics applications ? Ideal work for the WOLF gentle cell sorter

Aug 2, 2024

The field of genomics and computational biology has progressed immensely over the last decade and new single-cell...

Scaling Whole-Genome Sequencing to >50,000 single cells using cellenONE

Jul 16, 2024

cellenONE technology enabled the creation of tens of thousands of high-quality single-cell genomes, paving the way for...

Theranostics: From Mice to Men and Back

Jun 25, 2024

Recorded webinar
Presenters: Prof. Dr. Ken Herrmann and Prof. Dr. Katharina Lückerath – Moderator: Hannah Notebaert

Oct 4, 2024

Orion 2024 AACR poster: 17-plex single-step stain and imaging of cell Lung Carcinoma

Jun 21, 2024

RareCyte Orion is a benchtop, high resolution, whole slide multimodal imaging instrument. A combination of quantitative...

Hypoxia in the Tumor Immune Microenvironment (TIME)

Jun 6, 2024

Thursday, 11 July 2024, 16:00 CET | 10:00 EST
Zaver M. Bhujwalla, PhD...

X-RAD 320 for irradiation therapy during quantifying study for in vivo collagen reorganization

Jun 5, 2024

Quantifying in vivo collagen reorganization during immunotherapy in murine melanoma with second harmonic generation...

Oct 4, 2024

Use of MRI and microCT to evaluate gene therapy for the treatment of discogenic back pain

Jun 4, 2024

MRI images were obtained using the 9.4T Bruker BioSpec system, equipped with 40 mm 1H quadrature volume resonator, and...

Show all topics (10)

A carboxymethyl dextran-based polymeric conjugate as the antigen carrier for cancer immunotherapy

Sep 18, 2018

Antigen-specific cytotoxic T lymphocytes (CTLs), which eliminate target cells bearing antigenic peptides presented by surface major histocompatibility complex (MHC) class I molecules, play a key role in cancer immunotherapy. However, the majority of tumors are not immunologically rejected since they express self-antigens which are not recognized by CTLs as foreign. To foreignize these tumors for CTL-mediated immunological rejection, it is essential to develop carriers that can effectively deliver foreign antigens to cancer cells.

Do you want to learn more? Read this interesting article!

Scientific paper

Application

Get more info